Monte Rosa Therapeutics, Inc. (GLUE) Misses Q2 EPS by 1c

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q2 EPS of ($0.71), $0.01 worse than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
• J.P. Morgan cuts NIO to Neutral, slashes price target on weak demand outlook